ARS Pharmaceuticals announced its third‑quarter 2025 financial results today, reporting total revenue of $32.5 million, of which $31.3 million came from neffy product sales in the United States.
The company’s cash, cash equivalents and short‑term investments rose to $288.2 million, giving it a runway to fund operations through the cash‑flow break‑even point.
ARS also confirmed that it will host a conference call and webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results and provide additional commentary on its commercial strategy.
These earnings provide the first quarterly financial data since the launch of neffy, offering investors a view of the product’s commercial traction and the company’s financial health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.